Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All questions

Safety: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

12 questions · 4 sources

Safety

How often does Enhertu cause lung disease (ILD) in HER2-low breast cancer?

Note: DESTINY-Breast06: HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy, adjudicated drug-induced ILD, ENHERTU n=434 vs chemotherapy n=417 (table columns are Grades 1 to 5 and all grades). DESTINY-Breast04: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients, ENHERTU n=371. The last passage is the pooled safety population of the Prescribing Information (2233 patients with several tumor types treated with 5.4 mg/kg).

Does Enhertu cause neutropenia (low neutrophil count)?

Note: The second passage is the pooled safety population (2233 patients with several tumor types treated with 5.4 mg/kg). The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.

Does Enhertu cause heart problems (left ventricular dysfunction)?

“Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular dysfunction (LVD) has been observed with anti-HER2 therapies, including ENHERTU. Assess left ventricular ejection fraction (LVEF) prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVD through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.” (opens the source at this quote in a new tab)

Note: The incidence figure is from the pooled safety population (2233 patients with several tumor types treated with 5.4 mg/kg).

Does Enhertu lower platelet counts (thrombocytopenia)?

Note: The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.

Side effects

What are the most common Enhertu side effects in HER2-low or HER2-ultralow breast cancer?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Rates are from the DESTINY-Breast06 safety population (ENHERTU n=434; HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy).

How do Enhertu side effects compare with chemotherapy in DESTINY-Breast06?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Columns, in order: ENHERTU 5.4 mg/kg (n=434) all grades and Grades 3-4, then chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417) all grades and Grades 3-4, as percentages. Several terms group related events, as defined in the footnotes on the source page.

What were the most common Enhertu side effects in DESTINY-Breast04?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: Rates are from the DESTINY-Breast04 safety population (ENHERTU n=371; HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients).

How often were Enhertu side effects serious or fatal in DESTINY-Breast06?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).

How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast06)?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).

How often were Enhertu side effects serious or fatal in DESTINY-Breast04?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).

How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast04)?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).

Does Enhertu cause hair loss?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: DESTINY-Breast06. First row: ENHERTU (n=434) all grades and Grades 3-4, then chemotherapy (n=417) all grades and Grades 3-4, as percentages. Second row: ENHERTU Grades 1, 2, 3, and 4, as percentages.